A multicenter, retrospective analysis assessing the efficacy of combination systemic therapies in patients with nonclear cell renal cell carcinoma
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Axitinib (Primary) ; Bevacizumab (Primary) ; Everolimus (Primary) ; Ipilimumab (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ORACLE
- 04 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology